RT Journal Article
SR Electronic
T1 A Neanderthal OAS1 isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20212092
DO 10.1101/2020.10.13.20212092
A1 Sirui Zhou
A1 Guillaume Butler-Laporte
A1 Tomoko Nakanishi
A1 David Morrison
A1 Jonathan Afilalo
A1 Marc Afilalo
A1 Laetitia Laurent
A1 Maik Pietzner
A1 Nicola Kerrison
A1 Kaiqiong Zhao
A1 Elsa Brunet-Ratnasingham
A1 Danielle Henry
A1 Nofar Kimchi
A1 Zaman Afrasiabi
A1 Nardin Rezk
A1 Meriem Bouab
A1 Louis Petitjean
A1 Charlotte Guzman
A1 Xiaoqing Xue
A1 Chris Tselios
A1 Branka Vulesevic
A1 Olumide Adeleye
A1 Tala Abdullah
A1 Noor Almamlouk
A1 Yiheng Chen
A1 Michaël Chassé
A1 Madeleine Durand
A1 Michael Pollak
A1 Clare Paterson
A1 Hugo Zeberg
A1 Johan Normark
A1 Robert Frithiof
A1 Miklós Lipcsey
A1 Michael Hultström
A1 Celia M T Greenwood
A1 Claudia Langenberg
A1 Elin Thysell
A1 Vincent Mooser
A1 Vincenzo Forgetta
A1 Daniel E. Kaufmann
A1 J Brent Richards
YR 2020
UL http://medrxiv.org/content/early/2020/12/24/2020.10.13.20212092.abstract
AB Proteins detectable in peripheral blood may influence COVID-19 susceptibility or severity. However, understanding which circulating proteins are etiologically involved is difficult because their levels may be influenced by COVID-19 itself and are also subject to confounding factors. To identify circulating proteins influencing COVID-19 susceptibility and severity we undertook a large-scale two-sample Mendelian randomization (MR) study, since this study design can rapidly scan hundreds of circulating proteins and reduces bias due to reverse causation and confounding. We identified genetic determinants of 931 circulating proteins in 28,461 SARS-CoV-2 uninfected individuals, retaining only single nucleotide polymorphism near the gene encoding the circulating protein. We found that a standard deviation increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (N = 4,336 cases / 623,902 controls; OR = 0.54, P = 7×10−8), COVID-19 hospitalization (N = 6,406 / 902,088; OR = 0.61, P = 8×10−8) and COVID-19 susceptibility (N = 14,134 / 1,284,876; OR = 0.78, P = 8×10−6). Results were consistent in multiple sensitivity analyses. We then measured OAS1 levels in 504 patients with repeated plasma samples (N=1039) with different COVID-19 outcomes and found that increased OAS1 levels in a non-infectious state were associated with protection against very severe COVID-19, hospitalization and susceptibility. Further analyses suggested that a Neanderthal isoform of OAS1 affords this protection. Thus, evidence from MR and a case-control study supported a protective role for OAS1 in COVID-19 outcomes. Available medicines, such as phosphodiesterase-12 inhibitors, increase OAS1 and could be explored for their effect on COVID-19 susceptibility and severity.Competing Interest StatementJBR has served as an advisor to GlaxoSmithKline and Deerfield Capital.Funding StatementThe Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante (FRQS). SZ is supported by a CIHR fellowship and a FRQS fellowship. GBL is supported by the a CIHR scholarship, and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. TN is supported by Research Fellowships of Japan Society for the Promotion of Science (JSPS) for Young Scientists. JBR is supported by a FRQS Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. BQC-19 is funded by FRQS, Genome Quebec and the Public Health Agency of Canada. These funding agencies had no role in the design, implementation or interpretation of this study. VM is supported by a Canada Excellence Research Chair. The Kaufmann lab COVID-19 work is supported by the CIHR/CITF (VR2-173203), AmFAR (110068-68-RGCV) the CFI and FRQS. RF is supported by Swedish Research Council (2014-02569 and 2014-07606). MH is supported by a SciLifeLab/KAW national COVID-19 research program project grant (KAW 2020.0182).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All cohorts contributing cohorts to COVID-19 HGI received ethics approval from their respective research ethics review boards. The Biobanque Quebecoise de la COVID-19 (BQC19) received ethical approval from the IRB of JGH and the CHUM.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from proteomics studies and GTEx consortium are available from the referenced peer-reviewed studies or their corresponding authors, as applicable. Summary statistics for the COVID-19 outcomes are publicly available for download on the COVID-19 HGI website (www.covid19hg.org). Applicants are invited to apply for access to BQC19 data from the JGH hospital (https://www.mcgill.ca/genepi/mcg-covid-19-biobank) and/or the BQC19 (bqc19.ca).